- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- August 2023
- 115 Pages
Global
From €1924EUR$1,990USD£1,653GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 182 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- December 2023
- 157 Pages
Global
€4829EUR$4,995USD£4,148GBP
- Report
- January 2022
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Report
- March 2021
- 48 Pages
Global
€21269EUR$22,000USD£18,269GBP
- Report
- January 2019
- 212 Pages
Global
From €21269EUR$22,000USD£18,269GBP
- Report
- March 2018
- 18 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- March 2019
- 195 Pages
Global
From €10630EUR$10,995USD£9,130GBP
- Drug Pipelines
- November 2020
- 75 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Drug Pipelines
- November 2019
- 75 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- September 2019
- 70 Pages
Global
From €3142EUR$3,250USD£2,699GBP
- Report
- January 2021
- 142 Pages
China, Global
From €3000EUR$3,324USD£2,667GBP
- Report
- September 2022
- 58 Pages
Global
From €1934EUR$2,000USD£1,661GBP
Teriparatide is a synthetic form of parathyroid hormone used to treat endocrine and metabolic disorders. It is used to treat osteoporosis in postmenopausal women and men at high risk of fracture, as well as to treat osteoporosis in men and women with glucocorticoid-induced osteoporosis. It is also used to treat Paget's disease of bone in adults. Teriparatide is administered as a subcutaneous injection and is available in both brand-name and generic forms.
Teriparatide is a relatively new drug in the endocrine and metabolic disorders market, but it has been gaining traction in recent years. It is a safe and effective treatment for osteoporosis and other bone-related disorders, and its use is expected to continue to grow.
Some companies in the Teriparatide market include Eli Lilly, Amgen, and Teva Pharmaceuticals. Show Less Read more